Induction of Advanced Therapy

Objective: Ensure safe start to advanced therapy 
Patient population: Adult patients (>18 years) with known diagnosis of IBD

Highlight Box

Pretherapy workup should be considered for all patients.


IBD Provider:

1. Prior to starting therapy, the patient should have the following completed:

a. Take history for hypertension/hyperlipidemia/heart failure, multiple sclerosis, diabetes, venous thromboembolism, current or past history of cancer and consider the age of the patient. If there is a known history of congestive heart failure, a baseline echocardiogram is recommended (at the physician's discretion). Note: Anti-TNF therapy is contraindicated for patients with congestive heart failure NYHA Class III and IV, and multiple sclerosis.

b. HAV IgG, HBsAg, HBsAb, HCV (HIV may also be considered if patient at high risk or high local prevalence) (PACE QPIs 6, 30)

c. Routine IBD follow-up labs as indicated/appropriate (CBCD, FER, B12, Random glucose, ALB, ALP, ALT, TBIL, LPS, GGT, TSH, Vit D, CRP, AST, Fe, TIBC, ESR*)

d. Chest x-ray

e. TB Skin test, if immunosuppressed QuantiFERON –TB gold test recommended

f. EKG if considering S1P receptor modulator.

g. Vaccinations up to date (recommended: COVID, Influenza, Pneumococcal, MMR and Varicella zoster, Shingrix, Hepatitis A*) *optional

h. Arrange a fecal calprotectin kit prior to initiation of Advanced Therapy

2. Review insurance options and provide appropriate start-up sheets and Information sheets to the patient.

3. Depending on the choice of therapy, send a message to support staff to arrange a reassessment visit at 2-4 months to assess for primary response. As part of the assessment, report Harvey Bradshaw Index (HBI) or Partial Mayo (pMayo) 

Support Staff:

4. Arrange a clinic appointment for the patient at 2-4 months during induction and 3-6 months during the maintenance phase. Provide IBD follow-up blood requisition form and a fecal calprotectin kit or requisition to complete prior to their appointment (you may need to take into account the turnaround time for testing results). *applicable to pediatrics

See Health Maintenance protocol for monitoring of adverse effects and prevention of other diseases. 


Dosing and monitoring of Advanced Therapies

Agent Generic Name

Indicated For


Dose and Frequency

Class: Anti-TNF

Adalimumab+ biosimilars

Moderate to severe CD and UC

Tumor necrosis factor (TNF)

Induction: 160mg at week 0, 80mg at week 2

Maintenance: 40mg every other week starting at week 4

Infliximab + biosimilars

Moderate to severe CD and UC

Tumor necrosis factor (TNF)

Induction: 5mg/kg at week 0, 2, and 6Maintenance: 5mg/kg every 8 weeks starting at week 14 (escalate to 10mg/kg if inadequate response) 


Moderate to severe UC

Tumor necrosis factor (TNF)

Induction: 200mg at week 0, 2

Maintenance: 50mg-100mg every 4 weeks 

Class: Anti-integrin


Moderate to severe CD and UC

α-4-β-7 integrin

Induction: 300 mg IV at 0, 2 and 6 weeks

Maintenance: 300mg IV every 8 months OR 108mg subcutaneous injection every 2 weeks

Class: Cytokines


Moderate to severe CD and UC

IL-23 receptors

Induction: 600mg IV infusion at week 0, 4, 8

Maintenance: 360mg subcutaneous (on-body) injection every 8 weeks


Moderate to severe CD and UC

IL-12 and IL-23 receptors

Induction: IV, dosing based on weight:

≤55 kg: 260 mg as single dose

>55 kg to 85 kg: 390 mg as single dose

>85 kg: 520 mg as single dose

Maintenance: subcutaneous, begin maintenance dose (90 mg) 2 months after IV induction then continue 90 mg every 2 months

Class: Small molecules


Moderate to severe UC

Sphingosine 1-phosphate (S1P) receptors

Induction: 1mg/day of oral Ozanimod for 10 weeks

Maintenance: 1mg/day of oral Ozanimod


Moderate to severe UC

Janus kinase (JAK)

Induction: 10 mg twice daily for 2 months Maintenance: 5mg twice daily (or 10mg twice daily in selected patients)

If remission is not achieved and patient is at low risk of cardiovascular disease or thromboembolism: increase to 10 mg twice daily, then decrease to 5mg twice daily. 


Moderate to CD and severe UC

Janus kinase (JAK)

Induction: 45mg once daily for 8 weeks (patients with UC) or 12 weeks (patients with CD)

Maintenance: 15mg once daily or 30mg once daily (30mg once daily may be more effective for patients with more severe disease)

Please see the Loss of response/Partial response protocol in case of loss of response or partial response to Advanced Therapy. 


Mitrev et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017; 46(11-12):1037-1053.

Papamichael et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019; 17(9):1655-1668.

Download PDF version

Go Back to IBD Clinical Care Pathways